Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects

Synthesis, characterization and biological analysis of the complex [VO(Hdhp)2] (H2dhp = 2,3-dihydroxypyridine)

“…In our earlier experiments on the chronic oral administration of vanadyl sulfate to streptozotocin-induced diabetic rats, this salt was beneficial in reducing the ingestion of food and liquid and the blood levels of glucose, cholesterol, and triacylglycerol [5][6]. Similar tests were performed on non-insulin-dependent human diabetics who presented obesity and insulin resistance, who were treated with vanadyl sulfate and with sodium orthovanadate, resulting in moderately reduced levels of fasting plasma glucose and glycosylated hemoglobin [7][8] and a diminished insulin requirement [9]. The authors attributed to the vanadyl ion, an ability to enhance hepatic and peripheral sensitivity to insulin [7][8].…”

“…Similar tests were performed on non-insulin-dependent human diabetics who presented obesity and insulin resistance, who were treated with vanadyl sulfate and with sodium orthovanadate, resulting in moderately reduced levels of fasting plasma glucose and glycosylated hemoglobin [7][8] and a diminished insulin requirement [9]. The authors attributed to the vanadyl ion, an ability to enhance hepatic and peripheral sensitivity to insulin [7][8].…”

Pharmacodynamics and pharmacokinetics of the insulin-mimetic agent vanadyl acetylacetonate in non-diabetic and diabetic rats

“…Previous findings showed that vanadium compounds were effective for lowering plasma glucose levels in diabetic animals [2][3][4]. Two kinds of vanadium compounds, sodium metavanadate (SMV) and vanadyl sulfate (VS), were used in clinical trials, and exhibited significant insulin-mimetic effects in type I and type II human diabetic subjects [5][6][7]. Meanwhile, a significant decrease in cholesterol level was observed in diabetic patients received SMV [5].…”

Identification of a new anti-diabetic agent by combining VOSO4 and vitamin E in a single molecule: Studies on its spectral, thermal and pharmacological properties

“…In fact, recent clinical studies have demonstrated that a moderate decrease in the levels of fasting plasma glucose and glycosylated hemoglobin is observed in vanadyl sulfate-treated non-insulindependent diabetes mellitus (NIDDM) subjects with obesity and insulin resistance, after 3e4 weeks of treatment. This effect was thought to be due to an improvement of hepatic and peripheral insulin sensitivity [43,44]. Sodium orthovanadate has also been shown to be effective in lowering insulin requirements in insulindependent diabetes mellitus (IDDM) patients [45].…”

“…This ability may allow some of those with diabetes, a natural method to help lower blood sugar, taken less insulin or in some instances stop taking insulin altogether. Oral vanadyl sulfate improves insulin sensitivity in non-insulin-dependent diabetes mellitus (NIDDM) but not in obese nondiabetic subjects [1]. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with noninsulin-dependent diabetes mellitus [2].…”